Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have been given an average rating of “Hold” by the six analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $19.75.

CRBP has been the subject of several recent analyst reports. BidaskClub upgraded Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a report on Saturday, July 8th. Cantor Fitzgerald set a $24.00 target price on Corbus Pharmaceuticals Holdings and gave the stock a “buy” rating in a research note on Monday, July 17th. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research report on Wednesday, August 9th. Finally, ValuEngine downgraded Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/02/corbus-pharmaceuticals-holdings-inc-crbp-receives-consensus-recommendation-of-hold-from-analysts.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System acquired a new position in shares of Corbus Pharmaceuticals Holdings during the 3rd quarter worth about $108,000. Voya Investment Management LLC acquired a new stake in shares of Corbus Pharmaceuticals Holdings in the 2nd quarter valued at about $125,000. Evanson Asset Management LLC boosted its position in shares of Corbus Pharmaceuticals Holdings by 1.5% in the 2nd quarter. Evanson Asset Management LLC now owns 20,660 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 300 shares during the period. Capital Fund Management S.A. acquired a new stake in shares of Corbus Pharmaceuticals Holdings in the 2nd quarter valued at about $130,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Corbus Pharmaceuticals Holdings in the 1st quarter valued at about $148,000. Institutional investors own 31.77% of the company’s stock.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.